Zynerba Pharma CS (ZYNE)
$4.64 0.03 (0.65%)
16:00 EST ZYNE Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 62.92M
PE Ratio -1.66
Volume (Avg. Vol.) 564,429
Day's Range 4.45 - 4.74
52-Week Range 2.55 - 7.45
Dividend & Yield N/A (N/A)
ZYNE Stock Predictions, Articles, and Zynerba Pharma CS News
- From InvestorPlace
- From the Web
Investors are looking for the stocks that have the potential to lift their portfolios to new heights. These investments are the stocks with the strongest long-term growth narratives, capable of delivering massive returns.
Thinking about investing in medical cannabis? ZYNE stock is a lesser-known gem with transformative potential.
We are on the brink of a massive market opportunity. For instance, a new report by Grand View Research reveals that the global legal marijuana market size is expected to reach $66.3 billion by the end of 2025.
Looking for the real gains among the marijuana stocks? The key is to focus on firms using cannabis in medicine. Here are three biotech stocks moving headfirst into cannabis medicine.
Zynerba landed a new patent for its Zygel product to use cannabidiol as a treatment for Autism Spectrum Disorder, sending ZYNE stock ripping.
The CBD trend is heating up as its multiple uses gain traction and laws enable its use. Here are seven marijuana stocks to buy.
Investors have heard a ton about cannabis stocks and their ridiculous valuations. But Wall Street analysts say these pot stocks still have a lot of upside ahead.
Zynerba has a CBD gel that looks like a promising treatment for various neurological diseases. What does it mean for ZYNE stock?
There's some positive Zynerba Pharmaceuticals news concerning ZYNE stock on Tuesday that has it soaring to incredible heights.
Zynerba Pharmaceuticals (ZYNE) stock isn't done with its recent rally yet as the stock continues to climb higher on Thursday.
InvestorPlace's Best Stocks Contest is entering the homestretch! Here's how our experts' picks are holding up through the third quarter.
3 Stocks to Watch on Monday: Alphabet Inc (GOOGL), Zynerba Pharmaceuticals Inc (ZYNE) and Sony Corp (ADR) (SNE)
Zynerba Pharmaceuticals (ZYNE) crashes by nearly half, Alphabet (GOOGL) responds to anti-diversity letter and Sony (SNE) suffers yet another box-office disappointment.
Former leaders have fallen and former laggards in the Best Stocks for 2017 contest have risen to the occasion -- check out the rankings!
The experts' pick in the 10 Best Stocks for 2017 contest are trouncing the market so far. But where will these stocks to buy go from here?
Zynerba is working to bring its marijuana-based medications through trials and investors seem to be rewarding ZYNE stock.
The following stocks were the biggest movers and shakers in the Manufacturing sector today.
The Manufacturing sector saw plenty of trading activity today, including the following leaders and losers.
Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the 2020 Virtual Annual Meeting of the American Epilepsy Society (AES)
From Seeking Alpha
Zynerba Pharmaceuticals (NASDAQ:ZYNE) closed 5.9% higher, on new data from the Phase 2 Bright trial that further demonstrated the potential for Zygel (ZYN002) to improve the core behavioral symptoms of autism when administered as transdermal gel, in addition to stable standard of care in children and adolescents with moderate-to-severe autism spectrum disorder (ASD).Data will be presented at the International Child Neurology Congress & Annual Child Neurology Society Meeting, as well as at American Academy of Child and Adolescent Psychiatry Annual Meeting.Data show that patients receiving Zygel, achieved statistically significant caregiver-reported improvements compared to baseline across all subscales of the Autism Impact measure, which was designed to track incremental change in frequency and impact of core ASD symptoms.Zygel was very well tolerated and the safety profile was consistent with previously released data from other Zygel clinical trials.
Zynerba Pharmaceuticals Announces Oral Presentations at the Virtual American Academy of Child and Adolescent Psychiatry (AACAP) 2020 Annual Meeting
Navellier RatingsPowered by Portfolio Grader